Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia

Psychiatria Danubina

Volumn 25, Issue 4, 2013, Pages 389-397

  Krause, Daniela ^a   Weidinger, Elif ^a   Dippel, Catherine ^a   Riedel, Michael ^a,b   Schwarz, Markus J ^a   Müller, Norbert ^a   Myint, Aye Mu ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Vinzenz von Paul Hospital   (Germany)

Author keywords

Cytokines; Quetiapine; Risperidone; Schizophrenia; Tryptophan

Indexed keywords

CLOZAPINE; CYTOKINE; GAMMA INTERFERON; HALOPERIDOL; INTERLEUKIN 10; INTERLEUKIN 4; KYNURENINE; LIPOPOLYSACCHARIDE; NEUROLEPTIC AGENT; POLYINOSINIC POLYCYTIDYLIC ACID; QUETIAPINE; RISPERIDONE; TRYPTOPHAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOSTIMULATION; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; TRYPTOPHAN METABOLISM;

ANTIPSYCHOTIC AGENTS; CELL CULTURE TECHNIQUES; CYTOKINES; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TRYPTOPHAN;

EID: 84892414495     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Alexander KS, Wu HQ, Schwarcz R, Bruno JP: Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology 2012; 220:627-637.
2. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-738.
3. Belladonna ML, Orabona C, Grohmann U, Puccetti P: TGF-beta and kynurenines as the key to infectious tolerance. Trends in molecular medicine 2009; 15:41-49.
4. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H et al.: The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Progress in Neuro-psychopharmacology & Biological Psychiatry 2008; 32:42-48.
5. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N et al.: Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. Journal of Psychiatric Research 2012; 46:1421-1426.
6. Biswas SK & Lopez-Collazo E: Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009; 30:475-487.
7. Chang SH, Chiang SY, Chiu CC, Tsai CC, Tsai HH, Huang CY et al.: Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Research 2011; 187:341-346.
8. Dalman C, Allebeck P, Gunnell D, Harrison G, Kristensson K, Lewis G et al.: Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. The American Journal of Psychiatry 2008; 165:59-65.
9. Erhardt S, Olsson SK, Engberg G: Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009; 23:91-101.
10. Fila-Danilow A, Kucia K, Kowalczyk M, Owczarek A, Paul-Samojedny M, Borkowska P et al.: Association study of interleukin-4 polymorphisms with paranoid schizophrenia in the Polish population: a critical approach. Molecular Biology Reports 2012; 39:7941-7.
11. Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP et al.: Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Research 2010; 176:99-102.
12. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR: Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. Journal of Neurochemistry 1991; 56:2007-2017.
13. Geyer MA & Vollenweider FX: Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 2008; 29:445-453.
14. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ et al.: Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2006; 78:842-853.
15. Himmerich H, Schonherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U: Impact of antipsychotics on cytokine production in-vitro. Journal of Psychiatric Research 2011; 45:1358-1365.
16. Howes OD & Kapur S: The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 2009; 35:549-562.
17. Javitt DC: Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 2007; 78:69-108.
18. Kato T, Monji A, Hashioka S, Kanba S: Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophrenia research 2007; 92:108-115.
19. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ et al.: Th1, Th2 and Th3 cytokine alteration in schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry 2004; 28:1129-1134.
20. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009; 59:123-129.
21. Krause D, Matz J, Weidinger E, Wagner J, Wildenauer A, Obermeier M et al.: The association of infectious agents and schizophrenia. World J Biol Psychiatry 2010; 11:739-743.
22. Krause DL, Riedel M, Muller N, Weidinger E, Schwarz MJ, Myint AM: Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients. Inflammopharmacology 2012; 20:169-176.
23. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al.: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 2004; 51:199-214.
24. Lahti AC, Koffel B, LaPorte D, Tamminga CA: Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 1995; 13:9-19.
25. Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G et al.: Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia. Schizophr Bull 2012; 38:426-432.
26. Macdowell KS, Garcia-Bueno B, Madrigal JL, Parellada M, Arango C, Mico JA et al.: Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int J Neuropsychopharmacol 2011; 1-15.
27. Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M et al.: Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 1996; 21:39-50.
28. Meyer U, Feldon J, Yee BK: A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophrenia Bull 2009; 35:959-972.
29. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM: Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 1997; 159:2994-2999.
30. Muller N: The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub 2013; 25:292-298.
31. Muller N, Wagner JK, Krause D, Weidinger E, Wildenauer A, Obermeier M et al.: Impaired monocyte activation in schizophrenia. Psychiatry Research 2012; 198:341-6.
32. Myint AM: Kynurenines: from the perspective of major psychiatric disorders. The FEBS Journal 2012; 279:1375-1385.
33. Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S et al.: Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain, behavior, and Immunity 2011; 25:1576-1581.
34. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008; 63:801-808.
35. Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF: Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1991; 5:2652-2660.
36. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ: Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13:465-77.
37. Torrey EF, Bartko JJ, Lun ZR, Yolken RH: Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophrenia Bull 2007; 33:729-736.
38. Weschenfelder J, Sander C, Kluge M, Kirkby KC, Himmerich H: The influence of cytokines on wakefulness regulation: clinical relevance, mechanisms and methodological problems. Psychiatr Danub 2012; 24:112-126.
39. Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE et al.: Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011; 68:665-674.
40. Yasui H, Takai K, Yoshida R, Hayaishi O: Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci U S A 1986; 83:6622-6626.
41. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ et al.: Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011; 145:863-874.